Skip to main content
SpringerLink
Log in

Interleukin-3: a multilineage haemopoietic growth factor

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wiseman LR, Wagstaff AJ. Interleukin-3: a review of its pharmacological properties and clinical potential in patients with haematological disorders. Clin Immunother 1995; 3: 154–75

    Article  Google Scholar 

  2. Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994; 48: 731–60

    Article  PubMed  CAS  Google Scholar 

  3. British National Formulary No. 28. London: The Pharmaceutical Press, 1994; 351–2

  4. Physicians GenRx. New York: Data Pharmaceutica Inc., 1994; II 1980–2

  5. ABPI Data Sheet Compendium 1994–1995. London: Datapharma Publications Ltd., 1994; 1382–3

  6. Tolerability of colony-stimulating factors: better in practice than in theory. Drug Ther Perspect 1994 Feb 7; 3(2): 13–15

    Google Scholar 

  7. Seipelt G, Ganser A, Duranceyk H, et al. Induction of TNF-α in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. Br J Haematol 1993; 84: 749–51

    Article  PubMed  CAS  Google Scholar 

  8. Biesma B, Willemse PHB, Mulder NH, et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 1992 Sep 1; 80: 1141–8

    PubMed  CAS  Google Scholar 

  9. Dercksen MW, Hoekman K, ten Bokkel Huinink WW, et al. Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours. Br J Cancer 1992; 68: 996–1003

    Article  Google Scholar 

  10. Gianni AM, Siena S, Bregni M, et al. Recombinant human interleukin-3 hastens trilineage haematopoietic recovery following high-dose (7 g/m2) cyclophosphamide cancer therapy. Ann Oncol 1993 Nov; 4: 759–66

    PubMed  CAS  Google Scholar 

  11. Albin N, Douay L, Fouillard L, et al. In vivo effects of GM-CSF and IL-3 on haematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies. Bone Marrow Transplant 1994; 14: 253–9

    PubMed  CAS  Google Scholar 

  12. Dercksen MW, Hoekman K, Visser JJ, et al. Hypotension induced by interleukin-3 in patients on angiotensin-converting enzyme inhibitors [letter]. Lancet 1995; 345: 448

    Article  PubMed  CAS  Google Scholar 

  13. Ariad S, Geffen D. Role of colony-stimulating factors during high dosage chemotherapy. Clin Immunother 1994; 1: 449–59

    Article  Google Scholar 

  14. rGM-CSF may reduce costs associated with bone marrow transplants and cancer chemotherapy. Drug Ther Perspect 1994 Aug 8; 4(3): 1–4

    Google Scholar 

  15. Neumunaitis J. Use of hematopoietic growth factors in marrow transplantation. Curr Opin Oncol 1994; 6: 139–45

    Article  Google Scholar 

  16. Stein RS. Clinical use of growth factors in the myelodysplastic syndromes. Am J Med Sci 1994; 307: 369–7

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Interleukin-3: a multilineage haemopoietic growth factor. Drugs Ther. Perspect 5, 4–7 (1995). https://doi.org/10.2165/00042310-199505090-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505090-00002

Keywords

Search

Navigation